Vimarsana
Biggest News Aggregation in the World

Page 21 - Network Corp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Network Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Network Corp Today - Breaking & Trending Today

FCC Fines Dish Network $150K In First-ever Space Debris Penalty - Vimarsana News

FCC Fines Dish Network $150K In First-ever Space Debris Penalty

In a first, the Federal Communications Commission or FCC has issued a penalty related to space debris to Dish Network Corp. for failure to properly deorbit its EchoStar-7 satellite.

Inspiration Healthcare H1 Adj. Profit Declines - Vimarsana News

Inspiration Healthcare H1 Adj. Profit Declines

Inspiration Healthcare Group plc posted a loss before tax of 140 million pounds for the six months ended 31 July 2023 compared to profit of 885 million pounds, last year.

Dish Network is the first company to be fined for littering in outer space - Vimarsana News

Dish Network is the first company to be fined for littering in outer space

The Federal Communications Commission is fining Dish $150,000 for failing to properly de-orbit its EchoStar-7 satellite.

Earthstone Energy Reports Expiration Of HSR Act Waiting Period For Permian Acquisition - Vimarsana News

Earthstone Energy Reports Expiration Of HSR Act Waiting Period For Permian Acquisition

Earthstone Energy, Inc. (ESTE) announced Tuesday the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended, with respect to the previously-announced agreement for Permian Resources Corp.

Kineta Reports Positive Safety, Pharmacokinetic Data For KVA12123 From Ongoing Phase 1/2 Trial - Vimarsana News

Kineta Reports Positive Safety, Pharmacokinetic Data For KVA12123 From Ongoing Phase 1/2 Trial

Kineta, Inc. (KA) announced an update on its ongoing Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. KVA12123 cleared the first three monotherapy dose levels and was well tolerated with no dose limiting toxicities or cytokine related adverse events observed.